Strep vaccine stirs antibody production | Science News



Science News is a nonprofit.

Help us keep you informed.


Strep vaccine stirs antibody production

10:27am, October 18, 2005

From San Francisco, at a meeting of the Infectious Diseases Society of America

An experimental vaccine against the microbe that causes strep throat can induce a potent immune response in adults, a U.S.–Canadian research team reports. The finding suggests that the vaccine is ready for large-scale testing in adults and children.

The vaccine targets group A streptococcus bacteria, which cause scarlet fever, rheumatic fever, and kidney damage as well as the throat infections that often circulate among school-age children. It also aims at the microbes—sometimes called flesh-eating bacteria—responsible for necrotizing fasciitis.

Researchers have identified more than 120 variations, or subtypes, of group A strep, and each subtype has a slightly different version of a surface molecule called the M protein. The new vaccine uses portions of the M protein found on 26 of these subtypes to spur a broad immune reaction. Those subtypes include all of t

This article is only available to Science News subscribers. Already a subscriber? Log in now. Or subscribe today for full access.

Get Science News headlines by e-mail.

More from this issue of Science News

From the Nature Index Paid Content